OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX) in a research report sent to investors on Saturday morning. The brokerage issued a sell rating on the stock.

Separately, Needham & Company LLC reaffirmed a buy rating and issued a $4.25 price target on shares of OncoCyte in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of Hold and a consensus target price of $4.06.

OncoCyte Price Performance

NASDAQ:OCX opened at $3.00 on Friday. OncoCyte has a one year low of $2.08 and a one year high of $4.34. The company’s 50-day simple moving average is $3.12 and its 200 day simple moving average is $2.94.

OncoCyte (NASDAQ:OCX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share for the quarter. The company had revenue of $0.10 million during the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.